Madrigal Pharmaceuticals’ Promising Outlook: Buy Rating for Rezdiffra Amidst Enthusiastic Trial Enrollment and Regulatory Milestones
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...
360dx15h
Owlstone Medical Expanding Breath-Based Testing Using Endogenous, Exogenous VOCs
With the FDA approval this year of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic ...
GlobalData on MSN23h
Editas and Genevant team up to develop gene editing therapies
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...
Press Release Biocartis NV: Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting
CEST Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting Mechelen, Belgium, 23 October 2024 ...
Indiatimes21h
Mankind Pharma Share Price
Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 106,050.50 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...